Atlantic Coastal II Files S-4 and Investor Presentation on Abpro Deal

Atlantic Coastal Acquisition II today filed a registration statement and on its proposed deal with Abpro, The deal was announced in September at an implied equity value of $725 million. The transaction is expected to close in Q2 of 2024.

The target is a biotechnology company focused on next-generation antibody therapies for severe and life-threatening diseases.

Terms call for Abpro to own 72.5 million shares in the combined company. In addition, 14.5 million shares would be subject to an earnout agreement.

The SPAC raised $250 million in a January 2022 .

Brookline Capital Markets, a Division of Arcadia Securities, acted as a financial advisor to Abpro. Read more.


Source: Atlantic Coastal II Files S-4 and Investor Presentation on Abpro Deal